Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kowa to Start Independent Marketing of Livalo in the US in 2010
September 15, 2008
- PMDA Considers New System to Ensure Greater Post-Marketing Safety
September 15, 2008
- Otsuka to Codevelop Drug for Dry AMD with Acucela
September 15, 2008
- NICE to Recommend Lucentis to Treat Wet AMD under Health Insurance
September 15, 2008
- VEGF Trap-Eye Improves Vision in Patients with AMD: Bayer, Regeneron
September 15, 2008
- Pramipexole Improves Symptoms Associated with RLS: BI
September 15, 2008
- Greater Incentives Necessary to Further Increase Use of Generics: Dr Muto
September 15, 2008
- Novartis Has 8 NDAs Pending: Most Ever
September 15, 2008
- A Case of Diagnosis and Treatment of Effort Angina in Japan
September 15, 2008
- Jiho-Organized Industry Tour Group Visits Leiden Bio Science Park
September 15, 2008
- Korosho to Verify Quality of Generics of 10 APIs
September 15, 2008
- PM Yasuo Fukuda Steps Down
September 8, 2008
- Korosho to Demand \33.2 Bil. to Develop Drugs, Med. Devices
September 8, 2008
- Committee Recommends Approval of Generic Vancomycin from Mylan
September 8, 2008
- Draft Nat'l Medical Expenditure Optimization Plan Announced
September 8, 2008
- Thalidomide Safety Control Criteria Discussed by Study Group
September 8, 2008
- TOPICS／Society to Prevent Uterocervical Cancer Inaugurated
September 8, 2008
- CDFS Committee Recommends Conditional Approval of Thalidomide
September 8, 2008
- Seven APIs Recommended for Switching to OTC Status
September 8, 2008
- 16 Products (11 APIs) Recommended for NHI Price Listing
September 8, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…